Researchers have identified a functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting the gene. The finding could help guide treatment of patients with these cancers. Ryan B. Corcoran, HMS instructor in medicine at Massachusetts General Hospital, led the study.
